Acadia Pharmaceuticals Inc. (ACAD)

[Investors3]

ACADIA Pharmaceuticals Inc. [ACAD] – Is there any real value to ACAD Stock or is it vaporware?By Abby Carey -February 13, 2020

https://dwinnex.com/2020/02/13/acadia-pharmaceuticals-inc-acad-is-there-any-real-value-to-acad-stock-or-is-it-vaporware/

The share price of ACADIA Pharmaceuticals Inc. [NASDAQ: ACAD] inclined by $45.22, presently trading at $46.17. The company’s shares saw 114.15% gains compared to the lowest price in the period of the last 52 weeks, set at $21.56 recorded on 02/12/20. The last few days have been benevolent to the share price as ACAD jumped by +10.69% during the last week, even though the stock is still down by -1.20% compared to 4.49 of all time high it touched on 02/13/20. However, the stock had a poor performance during the past 3 months, roughly gaining 8.18%, while additionally gaining 101.97% during the last 12 months. ACADIA Pharmaceuticals Inc. is said to have a 12-month price target set at $55.80. That means that the stock has a strong potential to acquire 9.63% increase from the current trading price.

ACADIA Pharmaceuticals Inc. [NASDAQ:ACAD]: Analyst Rating and Earnings
Its stock price has been found in the range of 21.56 to 53.70. This is compared to its latest closing price of $45.22.

Keep your eyes peeled for this company’s upcoming financial results publication, which is slated for Wed 26 Feb (In 13 Days).

Fundamental Analysis of ACADIA Pharmaceuticals Inc. [ACAD]
Now let’s turn to look at profitability: with a current Operating Margin for ACADIA Pharmaceuticals Inc. [ACAD] sitting at -110.56 and its Gross Margin at +94.47, this company’s Net Margin is now -82.50%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is -60.77, and its Return on Invested Capital has reached -51.90%. Its Return on Equity is -60.22, and its Return on Assets is -53.03. These metrics suggest that this ACADIA Pharmaceuticals Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

What about valuation? This company’s Enterprise Value to EBITDA is -23.23. The Enterprise Value to Sales for this firm is now 18.91. ACADIA Pharmaceuticals Inc. [ACAD] has a Price to Book Ratio of 4.86.

Shifting the focus to workforce efficiency, ACADIA Pharmaceuticals Inc. [ACAD] earns $520,481 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 9.68 and its Total Asset Turnover is 0.48. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 8.76 and its Current Ratio is 8.83. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

ACADIA Pharmaceuticals Inc. [ACAD] has 155.02M shares outstanding, amounting to a total market cap of $7.01B. Its stock price has been found in the range of 21.56 to 53.70. At its current price, it has moved down by -14.02% from its 52-week high, and it has moved up 114.15% from its 52-week low.

This stock’s Beta value is currently 2.72, which indicates that it is 4.36% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 62.41. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is ACADIA Pharmaceuticals Inc. [ACAD] a Reliable Buy?
Shares of ACADIA Pharmaceuticals Inc. [ACAD], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.